Twist Bioscience TWST
Twist Bioscience Corp · Nasdaq · Biological Products, (No Diagnostic Substances)
$173.450.00%close on Oct. 29, 2026 · volume 1.8M · Yahoo Finance
Price, last 48 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 23, 2026 | Patrick John Finn President and COO | Sold | 2,245 | $134.59 | $302,152 |
| Oct. 9, 2026 | Adam Laponis Chief Financial Officer | Sold | 2,462 | $156.30 | $384,823 |
| Oct. 5, 2026 | Emily M. Leproust Chief Executive Officer, director | Sold 10b5-1 plan | 4,548 | $202.15 $200.44-$207.46 | $919,374 |
| Oct. 2, 2026 | Adam Laponis Chief Financial Officer | Sold | 8,057 | $188.88 | $1.52 million |
| Oct. 2, 2026 | Paula Green SVP of Human Resources | Sold | 10,088 | $188.88 | $1.91 million |
| Oct. 2, 2026 | Patrick John Finn President and COO | Sold | 25,714 | $188.88 | $4.86 million |
| Oct. 2, 2026 | Emily M. Leproust Chief Executive Officer, director | Sold 10b5-1 plan | 45,736 | $188.88 | $8.64 million |
| Oct. 2, 2026 | Dennis Cho See Remarks | Sold | 9,514 | $188.88 | $1.80 million |
| Oct. 2, 2026 | Robert F. Werner Chief Accounting Officer | Sold | 1,482 | $188.88 | $279,926 |
| Oct. 1, 2026 | Emily M. Leproust Chief Executive Officer, director | Sold 10b5-1 plan | 655 | $200.00 | $131,000 |
| Sept. 24, 2026 | Emily M. Leproust Chief Executive Officer, director | Sold 10b5-1 plan | 5,203 | $177.38 $175.23-$184.60 | $922,907 |
| Sept. 21, 2026 | Dennis Cho See Remarks | Sold | 348 | $165.49 | $57,591 |
Latest 12 of 40. Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.